Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer
Metastatic prostate cancer (mPCa) is currently incurable. Docetaxel-based chemotherapy, used as first-line treatment for advanced PCa, is marginally effective. As PCa is a heterogeneous disease, use of therapeutics targeting multiple pathways may improve its treatment outcome. Aneustat is first-of-a...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2017
|
| Online Access: | http://hdl.handle.net/2429/63631 |